Toronto, Canada — January 08, 2025 — NeuralCloud Solutions Inc. (“NeuralCloud”), a subsidiary of AI/ML Innovations Inc. (“AIML” or the “Company”) (CSE: AIML; OTCQB: AIMLF; FWB: 42FB), is pleased to announce that on December 12, 2025, the Company entered into a Commercial Agreement Term Sheet with Lakeshore Cardiology, a fully accredited comprehensive cardiac facility, to integrate NeuralCloud’s CardioYield™ AI visualization platform, powered by MaxYield™ signal-processing technology, into Lakeshore Cardiology’s clinical workflows.
Through this partnership, NeuralCloud will continue to expand into Holter and ambulatory cardiac monitoring environments, bringing AI-powered ECG analysis directly into clinical workflows. The collaboration aims to streamline data review and enable faster, more consistent interpretation of cardiac signals, supporting clinical decision-making. By integrating CardioYield™ into Lakeshore Cardiology’s established processes, the partnership demonstrates NeuralCloud’s commitment to embedding advanced AI tools seamlessly into real-world cardiology practices.
CardioYield™ is an AI-powered ECG visualization and reporting platform that uses MaxYield™, NeuralCloud’s proprietary, patent-pending signal-processing engine. The platform enables:
MaxYield™ isolates and labels key waveform components, including P waves, QRS complexes, and T waves, producing clean, machine-readable, beat-by-beat interval data suitable for downstream analytics and reporting.
The agreement outlines a staged rollout of CardioYield™, beginning with an internal validation using representative Holter files, followed by a limited paid trial within Lakeshore Cardiology to test the platform in real-world workflows. Once validated, the solution will be integrated into the clinic’s systems, with full deployment and cloud-based setup. Finally, pending Health Canada clearance, CardioYield™ will be commercially available for use across Lakeshore Cardiology’s cardiac monitoring operations.
“This agreement with Lakeshore Cardiology highlights NeuralCloud’s commitment to bringing AI-driven ECG analysis into clinical practice,” said Esmat Naikyar, President of NeuralCloud and Chief Product Officer at AIML. “CardioYield™ powered by MaxYield™ will provide clean, structured ECG data for faster, more reliable decision-making, benefiting both clinical teams and patients.”
Martina Magnotta, Manager of Operations of Lakeshore Cardiology, commented, “Partnering with NeuralCloud allows us to bring AI-enhanced insights into our Holter monitoring processes. CardioYield™ can potentially help our team quickly interpret cardiac signals, enhancing the quality of care for our patients.”
“This collaboration highlights the growing adaptability of NeuralCloud’s AI platform across clinical environments,” said Paul Duffy, Executive Chairman and CEO of AIML. “By bringing MaxYield™ and CardioYield™ into the Holter monitoring workflow, we’re helping redefine the standard for ECG analysis in real-world clinical practice.”
Lakeshore Cardiology is a fully accredited, comprehensive cardiac facility specializing in consultative, non-invasive diagnostic cardiology. The clinic’s mission is to provide high-quality patient care in a positive and comfortable environment, combining state-of-the-art diagnostic equipment with a compassionate approach.
The team includes Royal College of Physicians and Surgeons of Canada-certified specialists, registered cardiovascular technicians, cardiac sonographers, and nurses, all dedicated to optimizing medical care using comprehensive non-invasive techniques. Lakeshore Cardiology works closely with patients’ family doctors and primary healthcare providers to coordinate care, monitor heart conditions, adjust medications, and, when necessary, facilitate tertiary care referrals. The clinic is committed to improving patient outcomes, enhancing quality of life, and reducing stress and anxiety associated with cardiac health.
AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.
AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).
For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca .
Contact:
Blake Fallis
(778) 405-0882
On behalf of the Board of Directors:
Paul Duffy, Executive Chairman and CEO
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including risks associated with the implementation of the Company's products and services. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including with respect to the nature and timing of future operations and the receipt of all applicable regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.